Author(s): Dib N, Khawaja H, Varner S, McCarthy M, Campbell A
Abstract Share this page
Abstract The field of myocardial regeneration utilizing novel cell-based therapies, gene transfer, and growth factors may prove to play an important role in the future management of ischemic heart disease and cardiomyopathy. Phases I and II clinical trials have been published for a variety of biologics utilizing four methods of delivery: systemic infusion, intracoronary infusion, transvenous coronary sinus, and intramyocardial. This review discusses the advantages and disadvantages of the delivery approaches above.
This article was published in J Cardiovasc Transl Res
and referenced in Surgery: Current Research